- Clinical Trials
- April 2025
- 80 Pages
Global
From €1791EUR$2,000USD£1,527GBP
- Report
- May 2025
- 194 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- February 2025
- 200 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- March 2025
- 175 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- January 2025
- 175 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- June 2025
- 384 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- July 2024
Global
From €2911EUR$3,250USD£2,481GBP
€4344EUR$4,850USD£3,703GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €2239EUR$2,500USD£1,909GBP
- Clinical Trials
- April 2025
- 240 Pages
Global
From €2239EUR$2,500USD£1,909GBP
- Report
- July 2024
- 180 Pages
Global
From €2239EUR$2,500USD£1,909GBP
- Report
- January 2019
- 144 Pages
Global
From €2463EUR$2,750USD£2,100GBP
- Report
- May 2023
- 190 Pages
Global
From €2194EUR$2,450USD£1,871GBP
- Report
- January 2022
- 150 Pages
Global
From €5329EUR$5,950USD£4,543GBP
- Report
- November 2023
- 250 Pages
Global
From €2194EUR$2,450USD£1,871GBP
- Report
- April 2024
- 146 Pages
Global
From €2686EUR$2,999USD£2,290GBP
- Report
- May 2024
- 133 Pages
Global
From €5821EUR$6,499USD£4,962GBP
- Report
- May 2024
- 134 Pages
Global
From €5821EUR$6,499USD£4,962GBP
- Report
- August 2022
- 115 Pages
Global
From €4031EUR$4,500USD£3,436GBP
- Report
- March 2022
- 146 Pages
Global
From €6718EUR$7,500USD£5,726GBP
- Report
- February 2023
- 143 Pages
North America
From €3090EUR$3,450USD£2,634GBP

The Endothelin Receptor Antagonist (ERA) market is a subset of the cardiovascular drug market. ERA drugs are used to treat a variety of cardiovascular conditions, including hypertension, pulmonary arterial hypertension, and congestive heart failure. These drugs work by blocking the action of endothelin, a hormone that can cause constriction of the blood vessels. This helps to reduce blood pressure and improve blood flow. ERA drugs are generally well-tolerated and have few side effects.
The ERA market is highly competitive, with several major pharmaceutical companies offering products. These include Amgen, Bayer, Merck, Novartis, and Pfizer. Other companies, such as Actelion, Gilead, and United Therapeutics, also offer ERA drugs. These companies are continually researching and developing new drugs to improve the treatment of cardiovascular conditions. Show Less Read more